Neoplasms
Conditions
Keywords
mesothelin-expressing advanced solid cancers
Brief summary
To characterize the safety, tolerability, pharmacokinetics and immunogenicity of anetumab ravtansine in subjects with advanced solid cancers and with different degrees of hepatic or renal impairment
Interventions
All subjects received anetumab ravtansine 6.5 mg/kg BW (body weight) once every three weeks
Sponsors
Bayer
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female subjects aged ≥18 years * Histologically or cytologically confirmed, locally advanced or metastatic solid cancers known to express mesothelin on the tumor cell surface (e.g. predominantly epithelial \[\>=50% tumor component\] pleural or peritoneal mesothelioma, epithelial ovarian cancer \[including the fallopian tube or primary peritoneal\], adenocarcinoma of the pancreas, triple-negative adenocarcinoma of the breast, non-small-cell adenocarcinoma of the lung, endometrial cancer, serous uterine cancer, gastric cancer \[including the gastro-esophageal junction\], colon cancer, cholangiocarcinoma, thymic carcinoma, etc.). Subjects with resected primary cancers who have documented metastases or local recurrence are eligible. * Subjects must have no standard therapy available, or have actively refused standard therapy * Subjects must meet the criteria for one of the 4 treatment groups: * Group A: Adequate hepatic and renal function (controls) * Group B: Mild hepatic impairment, i.e. Grade A according to the Child-Pugh Classification (total score of 5 or 6) and adequate renal function * Group C: Moderate hepatic impairment, i.e. Grade B according to the Child-Pugh Classification (total score of 7, 8 or 9) and adequate renal function * Group D: Moderate renal impairment, i.e. eGFR (estimated glomerular filtration rate) \<60 and ≥30 mL/min per 1.73 m\*2 and hepatic function better than, or equal to mild impairment according to the Child-Pugh Classification (total score ≤6) * Adequate bone marrow function * Life expectancy of at least 12 weeks * ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1 (control and mild hepatic impairment groups), or 0-2 (moderate hepatic impairment and moderate renal impairment groups)
Exclusion criteria
* Subjects who have a previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study, except cervical carcinoma in situ, treated basal cell carcinoma, superficial noninvasive bladder tumors or any previous cancer curatively treated \>3 years before the start of anetumab ravtansine * Subjects who have new or progressive brain or meningeal or spinal metastases * Subjects who have Gilbert's syndrome or other benign congenital hyperbilirubinemia are not eligible for the mild or moderate hepatic impairment or moderate renal impairment groups. * Subjects who have a history or current evidence of bleeding disorder, i.e. any hemorrhage/bleeding event of CTCAE (Common Terminology Criteria for Adverse Events) Grade ≥2 bleeding within 4 weeks before the start of anetumab ravtansine * Subjects who have a history or current evidence of uncontrolled cardiovascular disease or hypertension. * Fridericia-corrected QT interval (QTcF) \>480 ms, heart rate ≥100 beats per minute (bpm) or ≤45 bpm, LVEF (left ventricular ejection fraction) \<50% * Subjects with corneal epitheliopathy or any eye disorder that may predispose the subjects to drug-induced corneal epitheliopathy or may interfere with diagnosis of treatment-emergent corneal epitheliopathy at the investigator's discretion in consultation with an ophthalmologist. * Subjects who have received systemic anticancer therapy (except pemetrexed, cisplatin, carboplatin and topical or intracavitary treatments with negligible absorption in systemic circulation ) within 4 weeks before the start of anetumab ravtansine, or within 5 half-lives of the anticancer agent before the start of anetumab ravtansine, whichever is longer. Mitomycin C or nitrosoureas must be excluded within 6 weeks before the start of anetumab ravtansine. * Subjects who have received radiotherapy within 4 weeks before the start of anetumab ravtansine * Use of drugs that, in the opinion of the investigator, have a strong potential for renal or hepatic toxicity within 2 weeks before the start of anetumab ravtansine until the EoT visit. * Use of strong cytochrome P450 3A4 (CYP3A4) inhibitors or strong CYP3A4 inducers within 2 weeks before the start of anetumab ravtansine until the EoT visit * Women who are pregnant or breast-feeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cmax for ADC, TA, DM4 and DM4-Me after single (first) dose administration of anetumab ravtansine (BAY94-9343) in Cycle 1 | From pre-dose until 504 hours post dose during cycle 1 |
| Number of subjects with treatment-emergent adverse events (TEAEs) and significant abnormalities in safety assessments related to anetumab ravtansine (BAY94-9343) in each of the 4 treatment groups | After the first application of the study drug up until the safety follow up visit, i.e., 30-35 days after the last dose of the study drug. |
| AUC for antibody drug conjugate (ADC), total antibody (TA), derivative 4 of maytansine (DM4), and S methyl derivate of DM4 (DM4-Me) after single (first) dose administration of anetumab ravtansine (BAY94-9343) in Cycle 1 | From pre-dose until 504 hours post dose during cycle 1 |
| AUC(0-tlast) for ADC, TA, DM4 and DM4-Me after single (first) dose administration of anetumab ravtansine (BAY94-9343) in Cycle 1 | From pre-dose until 504 hours post dose during cycle 1 |
Secondary
| Measure | Time frame |
|---|---|
| Cmax,md for ADC, TA, DM4 and DM4-Me in Cycle 3 | From pre-dose until 504 hours post dose during cycle 3 |
| AUC(0-tlast)md for ADC, TA, DM4 and DM4-Me in Cycle 3 | From pre-dose until 504 hours post dose during cycle 3 |
| Number of subjects with positive immunogenicity results for anti anetumab ravtansine (BAY94-9343) antibodies (anti drug antibody [ADA]) | From pre-dose on Day1 of Cycle 1 until the safety follow-up visit, i.e., 30-35 days after the last dose of the study drug |
| Number of subjects with positive immunogenicity results for anetumab ravtansine (BAY94-9343) neutralizing antibody (NAB) | From pre-dose on Day1 of Cycle 1 until the safety follow-up visit, i.e., 30-35 days after the last dose of the study drug |
Countries
France, Moldova
Outcome results
None listed